Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TLR4 | O00206 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22216375 | 0.99 | POLB (0.44) | POLBHPGDSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL22216157 | 0.96 | POLB (0.41) | POLBHPGDSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL22323003 | 0.93 | ALDH1A1 (0.40) | POLBHPGDSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL23000018 | 0.80 | TP53 (0.47) | HPGDSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL9685715 | 0.80 | POLB (0.39) | POLBHPGDSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL22999540 | 0.76 | FPR2 (0.42) | HPGDALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL1303947 | 0.76 | ALDH1A1 (0.39) | HPGDSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL4718434 | 0.76 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL978323 | 0.76 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL3367604 | 0.75 | ALDH1A1 (0.39) | HPGDSMN1; SMN2ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420637-B2 | Abnormal cannabidiols as agents for lowering intraocular pressure | ALLERGAN, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-7718830-B2 | Abnormal cannabidiols as agents for lowering intraocular pressure | ALLERGAN, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20100010027-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. | 2010-01-14 | — | — | US | disclosed |
| US-7618966-B2 | Abnormal Cannabidiols as agents for lowering intraocular pressure | ALLERGAN, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7612101-B2 | Abnormal cannabidiols as agents for lowering intraocular pressure | ALLERGAN, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20070249731-A1 | Abnormal cannabidiols as agents for lowering intraocular pressure | ALLERGAN, INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249581-A1 | Abnormal Cannabidiols as agents for lowering intraocular pressure | ALLERGAN, INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249602-A1 | 4-(1-isopropyl-4-methyl-1,2,5,6-tetra-hydropyridin-2-yl)-5-methylbenzene- 1,3-diol; glaucoma or ocular hypertension | ALLERGAN, INC. | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249581-A1 | Abnormal Cannabidiols as agents for lowering intraocular pressure | CNR2, CNR1, PTGIR | POLB 4018/4885HPGD 1521/4885SMN1; SMN2 4841/4885 |
| US-20070249731-A1 | Abnormal cannabidiols as agents for lowering intraocular pressure | CNR2, CNR1, PTGIR | POLB 4018/4885HPGD 1521/4885SMN1; SMN2 4841/4885 |
| US-20070249602-A1 | 4-(1-isopropyl-4-methyl-1,2,5,6-tetra-hydropyridin-2-yl)-5-methylbenzene- 1,3-diol; glaucoma or ocular hypertension | PTGIR, PTGS1, PTGIS | POLB 2322/4885HPGD 138/4885SMN1; SMN2 4863/4885 |
| US-20100010027-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | CNR2, CNR1, PTGIR | POLB 4018/4885HPGD 1521/4885SMN1; SMN2 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.